2022-05-26 18:39:41 SWTX SpringsWorks Therapeutics
GSK plc
05/26/22 05/2618:39 05/26/2218:39 | SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCOSpringWorks Therapeutics (SWTX) "announced initial clinical data from the Phase 1/2 study evaluating nirogacestat, SpringWorks' investigational gamma secretase inhibitor, in combination with BLENREP, GSK plc's (GSK) antibody drug conjugate targeting B-cell maturation agent, in patients with relapsed or refractory multiple myeloma. In addition, SpringWorks also highlighted long-term follow-up data from a Phase 2 study sponsored by the National Cancer Institute evaluating nirogacestat in patients with progressing desmoid tumors, which included follow-up on progression-free survival and long-term safety data.2 These data sets will be shared in poster sessions at the 2022 American Society of Clinical Oncology Annual Meeting, June 3-7, 2022 in Chicago. The objective of this sub-study of GSK's DREAMM-5 platform trial is to determine if low-dose BLENREP in combination with nirogacestat results in similar efficacy with an improved ocular toxicity profile compared to single-agent BLENREP at its approved dose and schedule. The study opened with a dose-exploration arm evaluating 0.95 mg/kg BLENREP Q3W combined with 100 mg BID nirogacestat dosed continuously, and subsequently moved into a cohort expansion arm. The target enrollment for the CE arm of the study is 70 patients randomized either to BLENREP 2.5mg/kg Q3W monotherapy or low-dose BLENREP plus nirogacestat combination using the same dose as the DE arm cohort. The study enrolled patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody. The poster being presented at ASCO includes data from a total of 24 patients treated with low-dose BLENREP + nirogacestat across the DE and CE cohorts and 14 patients treated with monotherapy BLENREP in the CE cohort. At the time of the March 4, 2022 data cut-off, the median of follow-up in the low-dose BLENREP plus nirogacestat DE cohort was 34.5 weeks (5-88 weeks), with durations of response exceeding one year in some patients. Data from the CE cohorts are not yet mature with a median duration of follow-up of 12 weeks available at the time of data cut-off. The CE cohorts utilized the KVA ocular toxicity grading scale; Grade 3 ocular adverse events occurred in 1/14 patients in the low-dose BLENREP plus nirogacestat combination compared to 7/14 patients in the BLENREP monotherapy arm. The DE cohort utilized the CTCAE-5 ocular toxicity grading scale; the low-dose BLENREP plus nirogacestat combination demonstrated Grade 3 ocular adverse events in 2/10 patients. At the time of data cut-off, the objective response rate of low-dose BLENREP plus nirogacestat across the DE and CE cohorts was 38%, with 17% of patients achieving a VGPR or better. The ORR of the BLENREP monotherapy control arm was 50%, with no patients achieving a VGPR or better." SpringsWorks Therapeutics
GSK plc
|
|
---|
Initiation
|
Shopify initiated with a Market Perform at JMP Securities »
05:51 07/05/22 07/0505:51 07/05/2205:51
SHOP
Shopify
JMP Securities analyst… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Credit Agricole downgraded to Hold from Buy at Deutsche Bank »
05:49 07/05/22 07/0505:49 07/05/2205:49
CRARY
Credit Agricole
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
BNP Paribas upgraded to Buy from Hold at Deutsche Bank »
05:49 07/05/22 07/0505:49 07/05/2205:49
BNPQY
BNP Paribas
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
888 Holdings resumed with a Buy at Deutsche Bank »
05:47 07/05/22 07/0505:47 07/05/2205:47
EIHDF
888 Holdings
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
UniCredit looking at Russia exit that it can reverse, Bloomberg reports »
05:46 07/05/22 07/0505:46 07/05/2205:46
UNCRY
UniCredit
UniCredit is weighing… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
JCDecaux downgraded to Underperform from Buy at BofA »
05:44 07/05/22 07/0505:44 07/05/2205:44
JCDXF
JCDecaux
BofA analyst Adrien de… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Tesla supplier Ganfeng Lithium probed for insider trading in China, FT reports »
05:43 07/05/22 07/0505:43 07/05/2205:43
TSLA
Tesla
Ganfeng Lithium, a Tesla… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Excelerate Energy upgraded to Overweight from Equal Weight at Wells Fargo »
05:42 07/05/22 07/0505:42 07/05/2205:42
EE
Excelerate Energy
Wells Fargo analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Fevertree Drinks upgraded to Neutral from Sell at Redburn »
05:41 07/05/22 07/0505:41 07/05/2205:41
FQVTF
Fevertree Drinks
Redburn analyst Charlie… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Powerlong Real Estate downgraded to Neutral from Buy at Goldman Sachs »
05:41 07/05/22 07/0505:41 07/05/2205:41
PWLNF
Powerlong Real Estate
Goldman Sachs analyst Yi… Story temporarily locked. |
Downgrade
|
Dai Nippon Printing downgraded to Neutral from Outperform at SMBC Nikko »
05:39 07/05/22 07/0505:39 07/05/2205:39
DNPLY
Dai Nippon Printing
SMBC Nikko analyst Takeru… Story temporarily locked. |
Downgrade
|
Talaris downgraded to Equal Weight from Overweight at Morgan Stanley »
05:38 07/05/22 07/0505:38 07/05/2205:38
TALS
Talaris Therapeutics
Morgan Stanley analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Proximus upgraded to Neutral from Sell at Citi »
05:37 07/05/22 07/0505:37 07/05/2205:37
BGAOF
Proximus
Citi analyst Martin… Story temporarily locked. |
Downgrade
|
Standard Chartered downgraded to Market Perform at Keefe Bruyette »
05:36 07/05/22 07/0505:36 07/05/2205:36
SCBFF
Standard Chartered
Keefe Bruyette analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Sparebanken Vest upgraded to Buy from Hold at Nordea »
05:35 07/05/22 07/0505:35 07/05/2205:35
SPIZF
Sparebanken Vest
Nordea analyst Ulrik… Story temporarily locked. |
Downgrade
|
Texas Instruments downgraded to Hold from Buy at DZ Bank »
05:33 07/05/22 07/0505:33 07/05/2205:33
TXN
Texas Instruments
DZ Bank analyst Ingo… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Fielmann downgraded to Hold from Buy at HSBC »
05:31 07/05/22 07/0505:31 07/05/2205:31
FLMNF
Fielmann
HSBC analyst Paul… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Tomra Systems initiated with a Buy at Kepler Cheuvreux »
05:29 07/05/22 07/0505:29 07/05/2205:29
TMRAY
Tomra Systems
Kepler Cheuvreux… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Boohoo downgraded to Neutral from Outperform at Exane BNP Paribas »
05:29 07/05/22 07/0505:29 07/05/2205:29
BHOOY
Boohoo
Exane BNP Paribas analyst… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Burberry downgraded to Neutral from Outperform at Exane BNP Paribas »
05:28 07/05/22 07/0505:28 07/05/2205:28
BURBY
Burberry
Exane BNP Paribas analyst… Story temporarily locked. ShowHide Related Items >><<
|
Periodicals
|
Indictment of Alvin Chau reveals vast criminal conspiracy, NIkkei reports »
05:28 07/05/22 07/0505:28 07/05/2205:28
LVS
Las Vegas Sands
MGM Resorts
Wynn Resorts
Melco Resorts & Entertainment
Macao junket boss Alvin… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Asos upgraded to Neutral from Underperform at Exane BNP Paribas »
05:28 07/05/22 07/0505:28 07/05/2205:28
ASOMY
Asos
Exane BNP Paribas analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Next plc upgraded to Outperform from Neutral at Exane BNP Paribas »
05:27 07/05/22 07/0505:27 07/05/2205:27
NXGPF
Next plc
Exane BNP Paribas analyst… Story temporarily locked. ShowHide Related Items >><<
|
Upgrade
|
Moneysupermarket.com upgraded to Buy from Hold at Liberum »
05:27 07/05/22 07/0505:27 07/05/2205:27
MNSKY
Moneysupermarket.com
Liberum analyst Ciaran… Story temporarily locked. |
Downgrade
| HSBC analyst Andrew… Story temporarily locked. ShowHide Related Items >><<
|